// App-Quantinova.ai

4090 : Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.

Researchers

Presenter

  • James C. Yao

Principal Investigators

  • Simron Singh

  • Roberto Buzzoni

  • Carlo Carnaghi

  • Edward M. Wolin

  • Jiri Tomasek

  • Markus Raderer

  • Harald Lahner

  • Maurizio Voi

  • Lida Bubuteishvili-Pacaud

  • Jeremie Lincy

  • Juan W. Valle

  • Gianfranco Delle Fave

  • Eric Van Cutsem

  • Do-Youn Oh

  • Jonathan R. Strosberg

  • Matthew H. Kulke

  • Marianne E. Pavel

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Istituto Europeo di Oncologia, Milano, Italy

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • IRCCS Istituto Clinico Humanitas, Rozzano, Italy

  • Markey Cancer Center, University of Kentucky, Lexington, KY

  • Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic

  • University Klinik f. Innere Medizin I, AKH, Wien, Austria

  • Universitaetsklinikum Essen, Zentrum f. Innere Medizin, Essen, Germany

  • Novartis Oncology, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

  • Institute of Cancer Studies, University of Manchester, The Christie Hospital, Manchester, United Kingdom

  • Azienda Ospedaliera Sant'Andrea - Universita La Sapienza, Rome, Italy

  • Digestive Oncology, University Hospitals Gasthuisberg/Leuven and KULeuven, Leuven, Belgium

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Dana-Farber Cancer Institute, Boston, MA

  • Charite-Universitatsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany

Locations

  • Canada

  • Czech Republic

  • Italy

  • Austria

  • Germany

  • Switzerland

  • United Kingdom

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroendocrine tumors

Biomarkers

  • N/A

Drug/Treatment

  • Somatostatin

  • Everolimus

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT01524783

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved